Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer:: Meta-analysis of randomized trials

被引:212
作者
McCulloch, M
See, C
Shu, XJ
Broffman, M
Kramer, A
Fan, WY
Gao, J
Lieb, W
Shieh, K
Colford, JM
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA
[2] San Francisco Oncol Associates, San Francisco, CA USA
[3] Chinese Acad Sci, Inst Biophys, San Francisco, CA USA
[4] Pine St Fdn, San Anselmo, CA USA
[5] Chinese Acad Tradit Chinese Med, Inst Informat, Beijing, Peoples R China
关键词
D O I
10.1200/JCO.2005.03.6392
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose Systemic treatments for advanced non-small-cell lung cancer have low efficacy and high toxicity. Some Chinese herbal medicines have been reported to increase chemotherapy efficacy and reduce toxicity. In particular, Astragalus has been shown to have immunologic benefits by stimulating macrophage and natural killer cell activity and inhibiting T-helper cell type 2 cytokines. Many published studies have assessed the use of Astragalus and other Chinese herbal medicines in combination with chemotherapy. We sought to evaluate evidence from randomized trials that Astragalus-based Chinese herbal medicine combined with platinum-based chemotherapy (versus platinum-based chemotherapy alone) improves survival, increases tumor response, improves performance status, or reduces chemotherapy toxicity. Methods We searched CBM, MEDLINE, TCMLARS, EMBASE, Cochrane Library, and CCRCT databases for studies in any language. We grouped studies using the same herbal combinations for random-effects meta-analysis. Results Of 1,305 potentially relevant publications, 34 randomized studies representing 2,815 patients met inclusion criteria. Twelve studies (n = 940 patients) reported reduced risk of death at 12 months (risk ratio [RR] = 0.67, 95% CI, 0.52 to 0.87). Thirty studies (n = 2,472) reported improved tumor response data (RR = 1,34; 95% CI, 1.24 to 1.46). In subgroup analyses, Jin Fu Kang in two studies (n = 221 patients) reduced risk of death at 24 months (RR = 0.58; 95% CI, 0.49 to 0.68) and in three studies (n = 411) increased tumor response (RR = 1.76; 95% CI, 1.23 to 2.53). Ai Di injection (four studies; n 257) stabilized or improved Karnofsky performance status (RR = 1.28; 95% Cl, 1.12 to 1.46). Conclusion Astragalus-based Chinese herbal medicine may increase effectiveness of platinum-based chemotherapy when combined with chemotherapy. These results require confirmation with rigorously controlled trials.
引用
收藏
页码:419 / 430
页数:12
相关论文
共 63 条
[1]
[Anonymous], 2001, SHANGHAI J TRADIT CH
[2]
[Anonymous], METAANAL DECISION AN
[3]
[Anonymous], 1997, Zhong Yi Za Zhi
[4]
OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[5]
Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis [J].
Burdett, S ;
Stewart, L .
LUNG CANCER, 2005, 47 (01) :81-83
[6]
Cao Y, 2003, ZHONGGUO ZHONGYI JIC, V9, P32
[7]
CAO Y, 2003, ZHONGGUO ZHONGYI JIC, V9, P595
[8]
CHEN GP, 2000, ZHEJIANG ZHONG XI JI, V10, P407
[9]
CHENG WC, 2003, ZHONGLIU YANJIU YU L, V15, P199
[10]
CHU GT, 1999, HE NAN ZHONGYIYAO XU, V14, P31